Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 3, 2011

Goodwin to Manufacture Alethia Preclinical mAb for Metastatic Cancer

  • Alethia Biotherapeutics selected Goodwin Biotechnology (GBI) as development and GMP manufacturing partner for its lead candidate, AB-16B5, designed to treat certain forms of cancer. The molecule is a mammalian cell line-based humanized IgG mAb.

    It targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT). “It has shown positive preclinical results in representative cancer models derived from various solid tumors," according to Mario Filion, Ph.D., Alethia’s EVO and CSO. Indications for AB-16B5 are metastatic tumors that include prostate, breast, pancreas, colon, and lung cancers, according to the company.

    Besides the EMT program, Alethia also has ovarian cancer and cancer-induced bone loss candidates in preclinical testing. AB-3D3 is being evaluated in animal models of ovarian cancer. It targets KAAG1, a cell-surface protein reportedly expressed in more than 90% of ovarian tumors and some normal tissues.

    For cancer-induced bone loss, the company’s AB-25E9 is being of evaluated in various models of the disease. It targets Siglec-15, a cell-surface protein with expression very specific to osteoclasts.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »